🧵1/3 Kudos to Cole Friedes, Melanie Berger, Lauren Linkowski, @EmilyLebow and colleagues in the Penn Brain Tumor Center for their publication today on clinical, molecular and immunologic determinants of #survival in #WHO-defined #IDH-wt #glioblastoma treated with #radiotherapy - a large real-world cohort study. @PennRadOnc @PennNSG @PennCancer @PennMedCSO link.springer.com/article/10…

Always a highlight of @ASTRO_org Meetings, the Awards ceremony🔥 Because we like to celebrate our community🥳 Huge shoutout to classmate, friend, role model, and mentoring force Helen Shih of MGH/MGB👏👏👏 (now she just needs to join #SoMe‼️) #ASTRO25 @DKirschMDPhD @AmyWisdom8 @EmilyLebow

Congratulations to Iris Gibbs, MD, FASTRO; Helen Shih, MD, MS, MPH, FASTRO; & Joachim Yahalom, MD, FASTRO on their 2025 ASTRO Mentorship awards!! They will be recognized at #ASTRO25 in San Francisco. @StanfordRadOnc @MassGeneralNews @MSK_RadOnc ow.ly/A1cB50WlXIa

#ASCO25: @StephenBagleyMD on CAR T cell for glioblastoma: “The treatment changed the trajectory of their disease.” Now in @NatureMedicine and on the @ASCO stage today. Abstract 102. @DrORourke2 spr.ly/6018N7k16

The @NCCN Foundation has announced MCC member, Kathryn Tringale, MD, MAS, as a 2025 Young Investigator Award recipient. This award recognizes her impact on cancer care through neuroimaging and biomarker research on neurotoxicity after CAR T-cell therapy: bit.ly/4iQpoo1.

#CARTcells for #DIPG #DMG clinical trial (1st arm) results are out today. Full Tweetorial coming, but first want to share the story of a patient whose #DIPG has disappeared for over 3 years. It is a milestone and moment of hope on a journey filled with so much grief. “There’s a lot of loss that led to this research,” Drew’s dad said. “I hope those families know that this success is because of them.” med.stanford.edu/news/all-ne…

Thanks, @HenningWillers! Great to present promising options for pts with locally advanced #lungcancer who are ineligible for chemoRT. @MSKCancerCenter @MSK_RadOnc

🧠☢️⚡️New in @JAMAOnc from @MSKCancerCenter #radonc grad Dr @EmilyLebow w/ Dr @yaoyu_md: Antibody-drug conjugates given concurrently with Stereotactic #radiotherapy #SRS were associated with ⬆️risk of symptomatic #radiation necrosis. More details here: jamanetwork.com/journals/jam…

🫁☢️New in @jitcancer from @MSKCancerCenter #radonc and @DanaFarber: This analysis of outcomes to #chemoradiation & #durvalumab in stage III non-small cell #lungcancer #NSCLC suggests that tumor aneuploidy is a promising predictive biomarker. #lcsm ➡️jitc.bmj.com/content/11/11/e…

Just out in @JAMAOnc - important data on risk factors for #brainmet necrosis with concurrent ADC SRS: understanding sequencing essential as CNS outcome data emerge @MSK_RadOnc @MSK_DeptOfMed @MSKNeurosurgery @EmilyLebow @yaoyu_md @Dr_Luke_Pike @Dr_N_Moss

Happy to share our work on SRS with concurrent ADCs, now out @JAMAOnc! In this study, led by @EmilyLebow, we investigated the risk of symptomatic radiation necrosis for pts receiving SRS and brain metastases. ADCs included T-DXd, T-DM1, and SG. (1/n) jamanetwork.com/journals/jam…

In this study, giving an antibody-drug conjugates (T-DXd, T-DM1, SG) concurrently with stereotactic radiotherapy was associated w/ higher risk of radiation necrosis. The absolute risk was low for small lesions, but increased rapidly w/ volume & prior RT. ja.ma/498qFCq

In @FrontiersIn we highlight the potential of #ctDNA to guide personalized therapy for patients with #lungcancer Thank you @NateraOncology, @Natera, @YoninaMG , Bob Li, @danielrgomez44, Andreas Rimner & many more at @MSK_RadOnc @MSKCancerCenter! 🔗 tinyurl.com/3pcmj6rd

🎙 SBRT for #sarcoma 🫁metastases achieved high rates of local control w/ low toxicity❗️🚨@OncoAlert @RadiotherapyOn1 📌retro single 🏥study 🥇🎯: Local failure 📊RESULTs 👉66 👥w/ 95 🫁metastases 👉local failure at 12 & 24 m 3.1% &7.4% 👉OS at 12 & 24 m 74% & 49% 👉Oligometastatic disease, intrathoracic only disease, and performance status🔄⬆️OS 👉N🚫 G3 Tox #radonc #oligometastases sciencedirect.com/science/ar…

☢️🫁 New in @RadiotherapyOn1 from Dr @EmilyLebow: We observed excellent long-term disease control with #SBRT for #sarcoma pulmonary metastases & potential for prolonged survival particularly among pts with oligometastatic disease at the time of SBRT. sciencedirect.com/science/ar…

🚨A #radonc away rotation @MSKCancerCenter means a month to explore the best of NYC: our cancer center, outstanding faculty, & what residency in the city that never sleeps really feels like🚕🌃🥯☕️ For July-December: Apply🔜via VSLO For June: 📩 medstudent@mskcc.org #match2024

It's a Match! Welcome to @MSKCancerCenter #radonc!! 🥳 🙌Kathryn Hockemeyer MD, PhD 🙌Gideon Haber, MD 🙌Elisa Liu, MD 🙌Revathi Ravella, MD 🙌Alexander Terry, MD 🙌Shoshana Rosenzweig, MD We're excited to have you join us in New York! #Match2023 #radoncMatch2023

New from former @MSKCancerCenter #proton Dr @AnnaLeeMDMPH with @imrtlee: Compared with previous reports of photon-based #reirradiation, pts are living longer with aggressive proton-ReRT; however, surviving pts remain at risk of early & late complications. jamanetwork.com/journals/jam…